Evidence from comparative genomic analyses indicating that Lactobacillus-mediated irritable bowel syndrome alleviation is mediated by the conjugated linoleic acid synthesis

2021 ◽  
Author(s):  
Yang Liu ◽  
Wei Xiao ◽  
Leilei Yu ◽  
Fengwei Tian ◽  
Gang Wang ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Linoleic Acid ◽  
Gut Microbiota ◽  
Acid Synthesis ◽  
Comparative Genomic ◽  
Low Grade ◽  
Genomic Analyses ◽  
Irritable Bowel ◽  
Low Grade Inflammation ◽  
Gut Microbiota Dysbiosis

Irritable bowel syndrome (IBS) is a chronic intestinal disorder accompanied by low-grade inflammation, visceral hypersensitivity, and gut microbiota dysbiosis. Several studies have indicated that Lactobacillus supplementation can help to alleviate...

scholarly journals The Gut Microbiota and Irritable Bowel Syndrome: Friend or Foe?

2012 ◽  
Vol 2012 ◽  
pp. 1-13 ◽  
Author(s):  
Uday C. Ghoshal ◽  
Ratnakar Shukla ◽  
Ujjala Ghoshal ◽  
Kok-Ann Gwee ◽  
Siew C. Ng ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Gut Microbiota ◽  
Pathogenic Bacteria ◽  
Bacterial Overgrowth ◽  
Small Intestinal Bacterial Overgrowth ◽  
Low Grade ◽  
Psychosomatic Disease ◽  
Irritable Bowel ◽  
Low Grade Inflammation ◽  
Qualitative Changes

Progress in the understanding of the pathophysiology of irritable bowel syndrome (IBS), once thought to be a purely psychosomatic disease, has advanced considerably and low-grade inflammation and changes in the gut microbiota now feature as potentially important. The human gut harbours a huge microbial ecosystem, which is equipped to perform a variety of functions such as digestion of food, metabolism of drugs, detoxification of toxic compounds, production of essential vitamins, prevention of attachment of pathogenic bacteria to the gut wall, and maintenance of homeostasis in the gastrointestinal tract. A subset of patients with IBS may have a quantitative increase in bacteria in the small bowel (small intestinal bacterial overgrowth). Qualitative changes in gut microbiota have also been associated with IBS. Targeting the gut microbiota using probiotics and antibiotics has emerged as a potentially effective approach to the treatment of this, hitherto enigmatic, functional bowel disorder. The gut microbiota in health, quantitative and qualitative microbiota changes, and therapeutic manipulations targeting the microbiota in patients with IBS are reviewed in this paper.

scholarly journals New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond

2017 ◽  
Vol 23 (36) ◽  
pp. 6593-6627 ◽  
Author(s):  
Emanuele Sinagra ◽  
Gaetano Cristian Morreale ◽  
Ghazaleh Mohammadian ◽  
Giorgio Fusco ◽  
Valentina Guarnotta ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Low Grade ◽  
Neuroendocrine Axis ◽  
Irritable Bowel ◽  
Low Grade Inflammation

scholarly journals Corticotropin-Releasing Factor and Toll-Like Receptor Gene Expression Is Associated with Low-Grade Inflammation in Irritable Bowel Syndrome Patients with Depression

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Song Jizhong ◽  
Wang Qiaomin ◽  
Wang Chao ◽  
Li Yanqing
Keyword(s):  
Gene Expression ◽  
Irritable Bowel Syndrome ◽  
Inflammatory Response ◽  
Psychiatric Symptoms ◽  
Corticotropin Releasing Factor ◽  
Low Grade ◽  
Lower Grade ◽  
Toll Like Receptor ◽  
Irritable Bowel ◽  
Low Grade Inflammation

The mechanism of low-grade inflammation in irritable bowel syndrome (IBS) is unclear; our research concentrates on the involvement of the corticotropin-releasing factor (CRF) and Toll-like receptor (TLR) gene expression in the process of low-grade inflammation in IBS patients with depression. This study suggests more IBS patients are presenting with the states of depression and anxiety. IBS patients with depression have shown a lower grade inflammatory response and an imbalance of the inflammatory response. CRF1, CRF2, TLR2, and TLR4 in IBS patients with depression are significantly higher than those without depression and controls. Thus, activation of the CRF-TLR associated pathways produces an inflammatory reaction, which can concurrently affect the digestive tract and the CNS and induce the corresponding digestive and psychiatric symptoms.

scholarly journals Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome (IBS): an evidence-based review

2014 ◽  
Vol 79 (2) ◽  
pp. 96-134
Author(s):  
Max Schmulson ◽  
María Victoria Bielsa ◽  
Ramón Carmona-Sánchez ◽  
Angélica Hernández ◽  
Aurelio López-Colombo ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Antibiotic Therapy ◽  
Low Grade ◽  
Evidence Based ◽  
Gastrointestinal Infections ◽  
Irritable Bowel ◽  
Low Grade Inflammation

scholarly journals Nodular lymphoid hyperplasia: A marker of low-grade inflammation in irritable bowel syndrome?

2016 ◽  
Vol 22 (46) ◽  
pp. 10198 ◽  
Author(s):  
Anna Chiara Piscaglia ◽  
Lucrezia Laterza ◽  
Valentina Cesario ◽  
Viviana Gerardi ◽  
Rosario Landi ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Lymphoid Hyperplasia ◽  
Low Grade ◽  
Nodular Lymphoid Hyperplasia ◽  
Irritable Bowel ◽  
Low Grade Inflammation

scholarly journals Simmering Innards: Does Irritable Bowl Syndrome Have an Immunological Basis?

2004 ◽  
Vol 18 (10) ◽  
pp. 601-603 ◽  
Author(s):  
Christopher N Andrews ◽  
Eldon A Shaffer
Keyword(s):  
Spinal Cord ◽  
Irritable Bowel Syndrome ◽  
Low Grade ◽  
Irritable Bowel ◽  
Low Grade Inflammation ◽  
Brain And Spinal Cord ◽  
The Brain

Not so long ago, physicians construed the irritable bowel syndrome (IBS) as being a neurotic trait: it was all in the head. Today most clinicians believe that the main abnormality lies in the brain (and spinal cord), which reacts abnormally to stimuli from the gut. Recent studies are identifying a basis for these neural changes - low grade inflammation in the gut - which may play a key role in IBS.

scholarly journals Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome

2018 ◽  
Vol 2018 ◽  
pp. 1-16 ◽  
Author(s):  
Simona Mihai ◽  
Elena Codrici ◽  
Ionela Daniela Popescu ◽  
Ana-Maria Enciu ◽  
Lucian Albulescu ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Gut Microbiota ◽  
Clinical Care ◽  
Low Grade ◽  
Public Health Burden ◽  
Inflammatory Status ◽  
Low Grade Inflammation ◽  
Gut Microbiota Dysbiosis

Persistent, low-grade inflammation is now considered a hallmark feature of chronic kidney disease (CKD), being involved in the development of all-cause mortality of these patients. Although substantial improvements have been made in clinical care, CKD remains a major public health burden, affecting 10–15% of the population, and its prevalence is constantly growing. Due to its insidious nature, CKD is rarely diagnosed in early stages, and once developed, its progression is unfortunately irreversible. There are many factors that contribute to the setting of the inflammatory status in CKD, including increased production of proinflammatory cytokines, oxidative stress and acidosis, chronic and recurrent infections, altered metabolism of adipose tissue, and last but not least, gut microbiota dysbiosis, an underestimated source of microinflammation. In this scenario, a huge step forward was made by the increasing progression of omics approaches, specially designed for identification of biomarkers useful for early diagnostic and follow-up. Recent omics advances could provide novel insights in deciphering the disease pathophysiology; thus, identification of circulating biomarker panels using state-of-the-art proteomic technologies could improve CKD early diagnosis, monitoring, and prognostics. This review aims to summarize the recent knowledge regarding the relationship between inflammation and CKD, highlighting the current proteomic approaches, as well as the inflammasomes and gut microbiota dysbiosis involvement in the setting of CKD, culminating with the troubling bidirectional connection between CKD and renal malignancy, raised on the background of an inflammatory condition.

Silencing interleukin 1α underlies a novel inhibitory role of miR‐181c‐5p in alleviating low‐grade inflammation of rats with irritable bowel syndrome

2019 ◽  
Vol 120 (9) ◽  
pp. 15268-15279 ◽  
Author(s):  
Li‐Jiang Ji ◽  
Fang Li ◽  
Ping Zhao ◽  
Li‐Ping Weng ◽  
Jun  Wei ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Low Grade ◽  
Inhibitory Role ◽  
Interleukin 1Α ◽  
Irritable Bowel ◽  
Low Grade Inflammation

scholarly journals Food Additives, Gut Microbiota, and Irritable Bowel Syndrome: A Hidden Track

2020 ◽  
Vol 17 (23) ◽  
pp. 8816
Author(s):  
Emanuele Rinninella ◽  
Marco Cintoni ◽  
Pauline Raoul ◽  
Antonio Gasbarrini ◽  
Maria Cristina Mele
Keyword(s):  
Irritable Bowel Syndrome ◽  
Gut Microbiota ◽  
Visceral Pain ◽  
Current Knowledge ◽  
Food Additives ◽  
Modern Human ◽  
Low Grade ◽  
Irritable Bowel ◽  
Few Data ◽  
The Impact

The interactions between diet, gut microbiota, and irritable bowel syndrome (IBS) have many complex mechanisms that are not fully understood. Food additives are one component of the modern human diet that deserves attention from science and government policies. This review aims at identifying the current knowledge about the impact of food additives on gut microbiota and their potential role in the development of IBS. To date, few data on the effect of food additives on gut microbiota in IBS patients are available. However, exposure to food additives could induce the dysbiosis and dysregulation of gut homeostasis with an alteration of the gut barrier and activation of the immune response. These microbial changes could exacerbate the gut symptoms associated with IBS, such as visceral pain, low-grade inflammation, and changes in bowel habits. Some additives (polyols) are excluded in the low fermentable oligo-, di- and monosaccharide, and polyol (FODMAP), diets for IBS patients. Even if most studies have been performed in animals, and human studies are required, many artificial sweeteners, emulsifiers, and food colorants could represent a potential hidden driver of IBS, through gut microbiota alterations. Consequently, food additives should be preventively avoided in the diet as well as dietary supplements for patients with IBS.

Sign in / Sign up

Export Citation Format

Share Document